.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX18_Letermovir.Letermovir_1

Information

Letermovir is an antiviral medication approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). It works as a CMV DNA terminase complex inhibitor and is currently approved and in clinical use.

Pharmacokinetics

Pharmacokinetic model in healthy volunteers after single intravenous administration.

References

1. Prohn, M, et al., & Cho, CR (2021). Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. CPT: pharmacometrics & systems pharmacology 10(3) 255–267. DOI:10.1002/psp4.12593 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33440077

2. Groll, AH, et al., & Badshah, C (2024). Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients. The Pediatric infectious disease journal 43(3) 203–208. DOI:10.1097/INF.0000000000004208 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38241643

3. Asari, K, et al., & Iwamoto, M (2022). Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single- and Multiple-Dose Administration in Healthy Japanese Subjects. Clinical pharmacology in drug development 11(8) 938–948. DOI:10.1002/cpdd.1081 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35238179

Revisions

• 06/2025 initial generated model